Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Funding This investigator-initiated project was funded by an unrestricted grant from the ResMed Foundation, San Diego, California, USA. Competing interests MEH reports grants from ResMed Foundation, ...

PAC is a chief investigator in a CPAP clinical trial funded by ResMed, and his department receives equipment support (CPAP machines) for an investigator-initiated study. Ethics approval This study was ...

After hours: February 4 at 5:38:17 PM EST ...

After hours: 7:17:07 p.m. EST ...